Recombinant Llama VHH-Human IgG Antibody for studying neutralization of SARS-CoV-2 and detection of 2019 -nCoV Spike Protein.
Catalog No. C19S1-642HL
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
C19S1-642HL-20 | 20 ug | $165 | |
C19S1-642HL-100 | 100 ug | $325 | |
C19S1-642HL-BULK | BULK | Contact Us |
Overview:
The severe acute respiratory syndrome related novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world in 2020 (1). The spike glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2 (2), which is also known to be the key component to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2). A receptor binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause higher motility rate (3).
References:
1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89.
2. Xiao X, et al: The SARS-CoV S glycoprotein. Cell Mol Life Sci. 2004, 61 (19-20): 2428-30.
3. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235
Host/Isotype/Clone:
Llama VHH-Human IgG Fc
Assay Data :
Sample activity data. For lot-specific data, please refer to the specific datasheet.
Assay Data :
Sample activity data. For lot-specific data, please refer to the specific datasheet.
Specificity:
Recognizes the 2019-nCoV Spike protein. Neutralizing activity validated for wild type Spike protein RBD and Spike protein RBD (N501Y) variant.
There are no related publications available for this product.
Acute Respiratory Distress Syndrome , Cardiovascular Disease, Cell Cycle, Cellular Stress, COVID19, Gastrointestinal Diseases , Infectious Diseases , Inflammation, Lung Diseases , Neurobiology, severe acute respiratory syndrome coronavirus 2 , Virology
STAY CONNECTED
Fax: 1-604-232-4601